TRAIL/APO-2L induces apoptosis in a variety of transformed cells and has potential as an anti-cancer therapeutic. The physiologic role of TRAIL is presumably more complex than merely activating caspase-mediated cell death. To shed light into TRAIL-mediated signaling, we used DNA microarrays to profile gene expression mediated by TRAIL in breast carcinoma cells. Primary response genes induced by TRAIL included a number of known NF-B-dependent genes such as cIAP2, A20, and E-selectin. Remarkably, global transcriptome analysis revealed that TRAIL also induced a cohort of genes related to the interferon-signaling pathway. Assessing interferon-induced gene expression suggested various points of interaction with the TRAIL signaling pathway. Interestingly, while we observed interferon-mediated up-regulation of TRAIL, we also demonstrated a concomitant TRAIL-mediated induction of interferon-␤. Combining TRAIL and interferon in vitro, synergistically induced apoptosis and caspase activation in breast cancer cells. Together, these data indicate multiple levels of molecular cross-talk between the two diverse cytokines with anti-tumor properties.
TRAIL/APO-2L is a member of the tumor necrosis factor (TNF) 1 cytokine family, which are type II transmembrane proteins that share homology in their extracellular domains (1) (2) (3) . A subset of these ligands is known to activate the cell death program including TNF, Fas ligand, DR3 ligand (TWEAK), and TRAIL. Of these, TRAIL has garnered the most interest therapeutically, as several studies have demonstrated in vivo tumoricidal activity in animal models without significant toxicity (4 -6) . Death ligands induce apoptosis by activating their cognate receptors on the surface of cells. These death receptors are members of the TNF receptor superfamily and include TNFRI, Fas (CD95/APO-1), DR-3 (death receptor-3), DR-4, DR-5, and DR-6 (1, 7). TRAIL specifically binds and induces apoptosis via DR-4 and DR-5 (8 -10) . Once activated, the death receptors, in general, bind the cytoplasmic adaptor molecule FADD, which functions as a molecular bridge to caspase-8, a protease at the apex of the cell death cascade (11, 12) . DR-4 and DR-5 have been proposed to indirectly bind FADD via the GTP-binding adaptor molecule, DAP3 (13) . By inducing proximity between pro-caspase-8 molecules, which possess weak protease activity, death receptor clustering facilitates trans-proteolysis and consequent activation of the cell death machinery (14, 15) .
TNF family ligands also have important nonapoptotic functions. For example, many death ligands (especially TNF␣) are known to activate transcription through NF-B and AP-1, leading to induction of inflammatory and immunomodulatory genes (16) . Activation of these nonapoptotic pathways involves a host of signaling mediators including TRADD, TRAF2, RIP, NIK, and others. Even FADD, a molecule required for endogenous activation of capsase-8, has functions outside of regulating cell suicide, including proposed roles in survival and proliferation (17) (18) (19) (20) (21) . FADD-deficient mice die in utero, suggesting that FADD has an important role in developmental pathways (22, 23) . However, relatively little is known about possible nonapoptotic functions induced by TRAIL.
To shed light into death ligand signaling and function, we studied gene expression profiles elicited by these cytokines. By using a functional genomics approach, we identified novel primary response genes induced by TRAIL and related death ligands. A dominant negative version of FADD (FADD-DN), inhibited much of the gene activation mediated by death ligands, further emphasizing the role of FADD in nonapoptotic signaling induced by death receptors. To our surprise, a cohort of genes induced by TRAIL at a late time point (Ն16 h), is classically associated with the interferon signaling pathway, including ISGF3␥, STAT-1, PKR, IL-6, and IFN␥R2, among others. Several genes identified by microarray were validated at the transcript level by Northern blot analysis and at the protein level by immunoblotting. While TRAIL transcript and protein were induced by interferons, we also demonstrated TRAIL-mediated up-regulation of IFN␤ transcript and protein.
Functionally, TRAIL and interferons had a synergistic effect in the induction of apoptosis in breast cancer cells. As our study demonstrates that TRAIL can induce interferon pathways, presumably via up-regulation of IFN␤, exposure of cancer cells to interferons may "prime" cells for apoptosis by TRAIL. The diverse gene expression profiles activated by the TRAIL signaling pathway may provide clues to diverse physiologic roles of TRAIL in vivo.
EXPERIMENTAL PROCEDURES
Cell Culture-MCF7 breast cancer cells, stably transfected with pCDNA3 and FADD-DN constructs (24) were grown in RPMI medium containing 10% fetal bovine serum and 0.5 mg/ml geneticin (Invitrogen) at 37°C in a humidified atmosphere of 10% CO 2 . SUM149 breast cancer cells (25) were grown in Ham's F12 medium containing 5% fetal bovine serum and supplemented with 5 g/ml insulin (Sigma) and 1 g/ml hydrocortisone (Sigma) at 37°C in a humidified atmosphere of 10% CO 2 . Treatment with various reagents was carried out on subconfluent plates (ϳ4 -6 million cells per 100-mm tissue culture plate) with fresh medium at the following concentrations: 1000 ng/ml TRAIL (4), 100 ng/ml TNF␣ (specific activity Ն 2 ϫ 10 7 units/mg; ED 50 Յ0.05 ng/ml) (Atlanta Biologicals), 100 ng/ml ␣FasAb (Alexis), 100 ng/ml TWEAK (TNF related weak inducer of apoptosis) (ED 50 Յ 10 ng/ml) (Atlanta Biologicals), 10 g/ml cycloheximide (Sigma), 5 M zVADfmk (Enzyme Systems Products), 1000 units/ml IFN-␣ (PBL Biomedical Labs), 1000 units/ml IFN-␤ (BIOSOURCE Int.), or 1000 units/ml IFN-␥ (R&D Systems).
Analysis of Cell Death by Nuclear Morphology-Cells were harvested by trypsinization, washed once with Dulbecco's phosphate-buffered saline, and fixed in 70% ice-cold ethanol at Ϫ20°C for 10 min. Cells were then washed twice with PBS and stained at room temperature for 10 min in Dulbecco's phosphate-buffered saline containing 100 g/ml propidium iodide (Sigma), 10 g/ml RNase A (Promega), and 0.01% Triton X-100. After an additional PBS wash, the cells were visualized by fluorescence microscopy. Propidium iodide stained the condensed fragmented chromatin of apoptotic nuclei intensely as opposed to diffuse nuclear staining associated with normal cells (24) . Three independent experiments were performed for each data point with over 250 cells counted per sample. Percent apoptosis was calculated as a mean ؎ S.D.
Microarray Procedures-DNA microarray analysis of gene expression was done essentially as described by the Brown Lab (available at www.microarrays.org) and in Refs. 26 and 27. The sequence-verified cDNA clones on the human cDNA microarray are listed in the Supplementary Material and are available from the Research Genetics web site (www.resgen.com). Purified PCR products, generated using the clone inserts as template, were spotted onto poly-L-lysine-coated microscope slides using an Omnigrid robotic arrayer (GeneMachines) equipped with quill-type pins (Majer Scientific). Based on the latest Unigene build-136, our 10,000 human cDNA microarray covers ϳ5996 unique, known, named genes and 2674 ESTs. Of these, 495 genes are present in duplicates, which serve as internal controls. Protocols for printing and post-processing of arrays are available in the public domain (www.microarrays.org).
Isolation of RNA-Approximately 4 -6 million cells per 100-mm tissue culture plate were washed with PBS, homogenized in Trizol (Invitrogen), and total RNA was isolated according to the manufacturer's protocol. An extra phenol-chloroform extraction was performed to improve the quality of RNA. RNA integrity was judged by denaturing formaldehyde-agarose gel electrophoresis. Total RNA was quantified and stored in aliquots at Ϫ80°C until use.
Labeling of cDNA Probes and Hybridization to cDNA Arrays-Fifteen micrograms of total RNA was routinely used as template for cDNA generation using reverse transcriptase (RT) (Invitrogen). Inclusion of amino allyl-dUTP (Sigma) in the RT reaction allowed for subsequent fluorescent labeling of cDNA using monofunctional NHS ester dyes (Amersham Bioscience, Inc.) as described at www.microarrays.org. In each experiment, fluorescent cDNA probes were prepared from an experimental RNA sample (coupled to monofunctional Cy5 NHS-ester) and an appropriate reference RNA sample (coupled to monofunctional Cy3 NHS-ester). The labeled probes were then hybridized to 10,000 human cDNA microarrays at 65°C overnight as described previously (www.microarrays.org). Fluorescent images of hybridized microarrays were obtained using a GenePix 4000A microarray scanner (www.axon. com, Axon Instruments).
Data Analysis-Primary analysis was done using the GenePix software package (Axon Instruments). Cy5 to Cy3 ratios are determined for the individual genes along with various other quality control parameters (e.g. intensity over local background). Furthermore, bad spots or areas of the array with obvious defects were manually flagged. Spots with small diameters (Ͻ50 microns) and spots with low signal strengths Ͻ350 fluorescence intensity units over local background in the more intense channel were discarded. Flagged spots were not included in subsequent analyses. These files were then imported into a Microsoft Access data base. Prior to clustering, the normalized median of ratio values of the genes were log base 2 transformed and filtered for the presence across arrays and selected for expression levels and patterns depending on the experimental set as stated in the figure legends. Average linkage hierarchical clustering of an uncentered Pearson correlation similarity matrix was applied using the program Cluster (28) , and the results were visualized with the program TreeView (28) .
Northern Blot Analysis-Thirty micrograms of total RNA was resolved by denaturing formaldehyde-agarose gel and transferred onto Hybond membrane (Amersham Bioscience, Inc.) by a capillary transfer set up. Hybridizations were performed as previously described (29) . Briefly, prehybridization was performed for 1 h at 65°C in a solution containing 1% bovine serum albumin (fraction V), 8% SDS, 0.5 M phosphate buffer, pH 7.0, and 1 mM EDTA, pH 8.0. Hybridization was performed in prehybridization buffer for 16 h at 65°C after adding the denatured probe at 2-3 ϫ 10 6 cpm/ml concentration. Blots were washed with 2 ϫ SSC, 0.1% SDS at room temperature three times over a period of 30 min. Subsequently, the blots were washed twice in 0.2 ϫ SSC, 0.1% SDS at 65°C for 60 min. Signal was visualized and quantitated by PhosphorImager. Data was culled using PhosphorImager software. The signal intensities were normalized against GAPDH signal intensities. For relative fold estimation, the ratio of the intensity of the respective transcript in the test sample over the transcript intensity in the reference sample was determined.
RT-PCR Analysis-One microgram of total RNA from experimental samples was reverse transcribed with Superscript reverse transcriptase (Invitrogen), using oligo(dT) and random hexanucleotide primer for first-strand cDNA synthesis. PCRs were performed directly on 1 l of first-strand cDNA using 500 nmol each of gene-specific primer (IFN␤: forward primer, 5Ј-tctcctccaaattgctctcctgtt-3Ј, reverse primer, 5Ј-cagaaggaggacgccgca-3Ј; IFN␥: forward primer, 5Ј-tttgggttctcttggctgttact-3Ј, reverse, primer 5Ј-acagaaaaataatgcagagccaaa-3Ј; and GAPDH: forward primer, 5Ј-cggagtcaacggatttggtcgtat-3Ј, and reverse primer, 5Ј-agccttctccatggtggtgaagac-3Ј) in a 100-l reaction volume comprised of 50 mM KCl, 10 mM Tris-HCl, pH 8.3, 1.5 mM MgCl 2 , 200 M of each deoxynucleotide triphosphate. PCR was carried out for initial denaturation at 94°C for 5 min, followed by 25, 42, and 45 cycles (for GAPDH, IFN␤, and IFN␥, respectively) of denaturation (94°C for 1 min), annealing (55°C for GAPDH and IFN␤, 59°C for IFN␥, for 1 min), and extension (72°C for 1 min) with 5 units of Taq polymerase (Invitrogen). This was followed by a final extension step of 72°C for 10 min. The products were analyzed on 2% agarose gels stained with ethidium bromide and visualized with ultraviolet light.
Immunoblot Analyses-Whole cell lysates prepared from MCF7 cells treated with a combination of zVADfmk, IFN-␤, and TRAIL were separated on SDS-PAGE. The proteins were blotted onto nitrocellulose membrane (Amersham Bioscience, Inc.) and blocked overnight in Trisbuffered saline containing 5% nonfat milk and 0.1% Tween 20 at 4°C. Immunoprecipitation and Western Blot-Cells were lysed in Nonidet P-40 lysis buffer (IP buffer) containing 50 mM Tris-HCl, pH 7.4, 1% Nonidet P-40 (Sigma), complete proteinase inhibitor mixture tablet (Roche Molecular Biochemicals) and incubated with 1.5 g of mouse monoclonal antibody against human IFN-␤ (PBL Biomedicals) in a total volume of 400 l of IP buffer and rotated end-over-end at 4°C for 90 min. Protein G-Sepharose beads (Amersham Bioscience, Inc.) equilibrated in IP buffer were added and the reactions were incubated for a further 60 min. IP reactions were washed three times with 1 ml of ice-cold IP buffer, resuspended in 40 l of SDS-PAGE sample buffer, boiled for 5 min, and 10 l of sample was run on 4 -20% SDS-PAGE gradient gels (Gradipore). The separated proteins were transferred onto PVDF membrane (Amersham Bioscience, Inc.). The membrane was incubated for 1 h in blocking buffer (Tris-buffered saline containing 0.1% Tween (TBS-T) and 5% nonfat dry milk). Biotinylated anti-human IFN-␤ (R&D systems) was applied at 1:10000 in TBS-T with 1% bovine serum albumin and incubated for 1 h at room temperature. After washing three times with TBS-T buffer, the membrane was incubated with streptavidin-horseradish peroxidase (Invitrogen) at 1:5000 in TBST with 1% bovine serum albumin for 1 h at room temperature. ECL was performed as described in the previous section.
Metabolic Labeling-MCF7 cells were split and grown overnight in 24-well tissue culture plates (Costar) at a density of 62,500 cells per well. Preincubation with 10 g/ml cycloheximide (Sigma) for 30 min was followed by incubation in Dulbecco's modified Eagle's medium minus methionine and cysteine for 15 min. The cells were then incubated in the above medium containing 250 Ci/ml Tran 35 S-label (L-methionine:L-cysteine 70:30), specific activity Ͼ1,000 Ci/mM (10 mCi/ ml) (ICN Radiochemicals) at both 4 and 24 h at 37°C in 10% CO 2 . Cells were harvested in 100 l of lysis buffer (1% Nonidet P-40, 0.02 M Tris, pH 7.4, and complete, EDTA-free protease inhibitor mixture tablet). Lysates were spotted on 2.4-cm glass microfiber (GF/C) filter (Whatman) and air dried. Labeled proteins were precipitated by soaking the filters in 20% trichloroacetic acid (JT Baker Inc.) for 4 min with gentle shaking. The filters were then washed in 70% alcohol, dried, and counted in Econo-Safe TM (Research Products Int. Corp) in a scintillation counter.
IFN␥ Enzyme-linked Immunosorbent Assay-96-Well plates (Nunc Immunoplate Maxisorb) were coated with 100 ng/ml anti-IFN-␥ mAb (PBL Biomedical Laboratories) and incubated overnight at 4°C. The plates were washed with PBS containing 0.05% Tween 20 (Fisher Biotech) and nonspecific binding sites were blocked with Blocker TM Blotto (Pierce) in PBS for 1 h at room temperature. All subsequent incubations were conducted at room temperature with shaking. The plates were washed and incubated for 1 h with different dilutions of purified IFN-␥ (Standard) and the total cell lysates (diluted 1:2) in dilution medium (PBS with 10% Blotto, 0.1% bovine serum albumin (Sigma), and 0.05% Tween 20. Plates were washed and incubated with the detection antibody, biotinylated rabbit polyclonal ␣-IFN-␥ Ab (1:500 in dilution medium) for 1 h. After washing, horseradish peroxidaseconjugated streptavidin (Jackson Immuno Research Laboratories, 1:20,000 in dilution medium) was added and plates were incubated for 30 min. After a final wash, 3,3Ј,5,5Ј-tetramethylbenzidine (Genzyme Diagnostics) was added, and plates were incubated in the dark for 15 min. The reaction was terminated using 1.5 N H 2 SO 4 . The plates were then read at dual wavelengths (465 and 590 nm) on a Bio-Tek microplate reader (Bio-Tek Instruments) and IFN-␥ concentrations were estimated using a standard curve based on dilutions of recombinant IFN␥ (R&D Biosystems).
Caspase 8 Substrate Cleavage Assay-SUM149 cells were grown at a density of 2.5 ϫ 10 4 cells per well overnight in 12-well tissue culture plates. Cells were lysed in buffer containing 20 mM Tris, pH 7.5, 150 mM NaCl, and 1% Triton X-100. The assay was carried out according to the manufacturer's protocol (Enzyme Systems Products). Briefly, 50 l of lysate was mixed with 50 l of 2 ϫ reaction buffer (200 mM HEPES, pH 7.5, 40% glycerol, 10 mM dithiothreitol, 1 mM EDTA) and incubated at 30°C for 30 min. Lysates were transferred to dark walled 96-well plates (BD) and caspase 8 flurometric substrate Ac-IETD-AFC (Enzyme Systems Products) was added at a 1 mM concentration. Fluorescence was recorded at 400 nM excitation and 530 nm emission using a Packard Fluorometer. Values obtained from three independent experiments were averaged and fluorescence intensity was plotted as arbitrary units.
RESULTS
Gene Expression Analysis-To study genes induced by activation of cell death receptors we used a 9984 element (10,000) cDNA microarray consisting of ϳ5996 known, named genes and 2674 ESTs (Unigene Build 136) (26) . Fluorescently labeled (Cy5) cDNA was prepared from total RNA from each experimental sample. A specific reference sample was paired with each experimental sample and labeled with a second distinguishable fluorescent dye (Cy3). Fig. 1 is an Eisen matrix representation that provides an overview of the 35 different experimental samples analyzed and includes: various control hybridizations (Fig. 1, columns 5 , 7-10, and 21 and 22), MCF7 and SUM149 cells treated with TRAIL (Fig. 1, columns 1 -4, 6, 11-15, and 20) or with other death inducing agents including TNF, ␣FasAb, or TWEAK (Fig. 1, columns 16 -19 ), MCF7-FADD-DN cells treated with various death ligands (Fig. 1 , columns [23] [24] [25] [26] , and cells treated with interferon-␣, -␤, or -␥ (Fig. 1, columns [27] [28] [29] [30] [31] [32] [33] [34] [35] . A hierarchical clustering algorithm was employed to group genes based on similarity in gene expression across all the samples tested (28) . Coordinated patterns of gene expression mediated by these cytokines were evident and selected clusters will be dissected in detail. The entire dataset presented in Fig. 1 is available in the Supplementary Material.
To focus on primary response genes induced by TRAIL in breast carcinoma cells, we used cycloheximide (CHX) to block protein synthesis, thereby inhibiting secondary and tertiary responses. CHX alone does not induce significant apoptosis in either MCF7 or SUM149 cells, in the time frame assessed (data not shown). As extended treatment with TRAIL causes induction of apoptosis in these cell lines (TRAIL, at 1000 ng/ml, significantly increases apoptosis within 3 and 5 h in SUM149 and MCF7 cells, respectively), we used the broad-spectrum caspase inhibitor z-VADfmk (zVAD) to block cell death, allowing for the study of gene expression alterations independent of apoptosis. While CHX and zVAD alter the expression of a limited set of genes, these changes were outside of the death ligand-specific response clusters (Fig. 1, columns 7-10 and 21  and 22) . Furthermore, zVAD and CHX mediated effects were negated by using these agents in the specific reference samples used for microarray analysis. The cluster diagram represents the ratio of hybridization of fluorescent cDNA probes prepared from each experimental RNA (labeled with Cy5) to the reference RNA (labeled with Cy3). These ratios are a measure of gene expression in the experimental samples (denoted as TEST) relative to their specific reference sample (denoted as REF) and are depicted according to the color scale provided. Red and green colors in the matrix represent genes that are up-and down-regulated, respectively, relative to the reference. Black color represents unchanged transcript level, while gray signifies missing data (NP, not present). Color saturation reflects the magnitude of the ratio relative to the median for each set of samples. Prior to hierarchical average linkage clustering, the data was filtered for a 2-fold (Ն2.0 or Յ0.5) change in the Cy5/Cy3 ratio, with ratio measurements available for at least 80% of the samples. Each column in the cluster diagram represents a single hybridization experiment between the test and reference samples and each row represents the expression pattern of a single gene across the different experiments. This dataset along with gene names can be found in our Supplementary Material. Abbreviations used, in alphabetical order: C, cycloheximide (10 g/ml); FADDdn, FADD dominant negative MCF7 cell line; IFN, interferon; M, MCF7-pCDNA3 cells; S, SUM149 cells; Urx, untreated; Z, zVADfmk (5 M). This broad overview identifies distinct subgroups considered in detail in the text.
Gene Expression Patterns Induced by TRAIL-Analysis of gene expression in breast cancer cells treated with TRAIL revealed, primarily, "up-regulation" of specific gene products. While selected genes were down-regulated (as evident in Fig.  1 ), they are not presented here and are included in the Supplementary Material. Our analysis of a time course of TRAILtreated MCF7 cells revealed three distinct clusters of up-regulated genes. In the "early" primary response cluster, genes were up-regulated between 1 and 4 h and declined to normal levels thereafter (Fig. 2, A, top panel, and B) . The "intermediate" cluster was comprised of genes that were up-regulated at the 4-h time point and remained elevated (Fig. 2, A, middle panel,  and C) . Finally, the "late" cluster contained genes that were up-regulated at 16 h and beyond (Fig. 2, A, bottom panel, and  D) . We next considered each cluster in some detail.
The early cluster of TRAIL-induced genes (Fig. 2B ) includes an activator of immediate early genes HCFC-1 (30) , an example of an immediate early gene INSIG-1 (31) , and transcriptional repressors, such as seven in absentia homolog-2 (SIAH-2) (32), Ras suppressor-1 (RSU-1) (33), and CDC-6 (34). Other notable genes in the early primary response cluster are the endothelial adhesion molecule, E-selectin, known to be regulated by NF-B (35, 36) , BNIP-3, a pro-apoptotic BCl-2 family mitochondrial protein (37) , and the CXC chemokine GRO1␣, which possesses antiapoptotic activity (38) .
The apoptotic threshold of cells may be regulated by intra- Fig. 1 for description of the convention used to represent changes in transcript levels. In most cases Human Genome Organization (HUGO) nomenclature has been used to designate genes. ESTs and down-regulated genes have not been included in the analysis and have been made available in our Supplementary Material. cellular Ca 2ϩ levels (39, 40) , and notably many Ca 2ϩ -modulating protein transcripts including calreticulin, KDELR2, and ERP70/PDIR were induced (Fig. 2B) . Other interesting genes in this cluster include: 1) antioxidants such as ␤-hydroxybutyrate dehydrogenase and stearoyl-CoA desaturase (SCD); 2) caspase substrates such as NEDD-4 (41) and MCM-3 (42); and 3) proteolytic enzymes such as metalloprotease 1 (PCOLNIII) and serine protease 23 (SPUVE). An LPS-induced molecule called MAIL, which possesses ankyrin repeats similar to IB proteins (43) , was also expressed at high levels during the 4-and 8-h time points of TRAIL treatment.
The intermediate primary response cluster contains several previously reported TNF-induced genes, providing independent validation of our system (Fig. 2C) . This group includes NF-B induced primary response genes such as A20, B94, and cIAP2. A20 and cIAP2 have both been shown to negatively regulate TNF-induced apoptosis (44, 45) , whereas less is known about the role of B94 (46) . A number of transcription factors were up-regulated in this cluster, including NF-B, JUN-D, BCL-6, and VDR. NF-B, and JUN-D (an AP-1 transcription factor) are known to be activated by TNF family members (16) . Curiously, BCL6, a transcriptional repressor, controlling germinal center formation (47, 48) , was found to be up-regulated by TRAIL. Similarly, the vitamin D3 nuclear receptor, VDR, that heterodimerizes with retinoid X receptor (RXR) upon ligand binding (49) , was induced by TRAIL between 4 and 16 h. VDR has been recently reported to induce apoptosis in human embryonic kidney cells (50) . Other noteworthy groups of genes in this cluster include: 1) adhesion/ cytoskeletal genes such as ICAM1, Kal1, Keratin10, and syntaxin 11; 2) antioxidants such as MnSOD, and AKR1C1; 3) protease/antiproteases such as serpin ␣3 and plasminogen activator, urokinase; and 4) many cytokines and inflammation associated molecules including IL-6, mCSF1, IFN␥R-2, MX-2, NK-4, MBL-2, MCP-1, MCP-3, and MCP-4.
The late cluster of TRAIL-induced genes revealed a cohort of interferon pathway related genes. This cluster, reproduced in two different cell lines, included interferon signaling molecules such as ISGF3␥, STAT1, N-myc-and -STAT interactor (NMI), and PKR (51) . Additional genes considered to be characteristic of the interferon pathway were also up-regulated by TRAIL including IFIT1, IFITM1, IFITM2, IFI-16, IFI-6 -16, IFN stimulated-15, HLA-A, HLA-C, HLA-F, PSME2, SP100, among others. TRAIL itself has been shown to be induced by interferons (52-55), and we observed up-regulation of TRAIL transcript only in this late cluster. Importantly, genes up-regulated at this late time point, but not known to be part of interferon pathway, were also identified, including MYD88, TLR3, transforming growth factor ␤1, phosphatase interacting protein-1, TFPI-2, aconitase 1, and galactose binding lectin 3.
Gene Expression Mediated by TRAIL-related Death Ligands-To determine whether the TRAIL induced cluster of IFN pathway genes is a specific response shared by other death ligands, we profiled breast cancer cells, treated with TRAIL, TNF, and anti-Fas antibody under similar conditions as used for treatment with TRAIL (treatment for 24 h in presence of zVAD, to block cell-death, and CHX to prevent protein synthesis). As shown in Fig. 3 , a common cluster of genes was found to be up-regulated by different death ligands, and these included the IFN pathway-related genes. Taken together, this would suggest that death ligands induce a common gene expression machinery, and that, specificity is achieved at the ligand/receptor interface.
To further establish that these gene clusters resulted specifically from death ligand induced signaling, we used a cell line that stably expresses a dominant negative derivative of FADD, MCF7-FADD-DN (24) . Upon treatment of these cells with the same set of death ligands, we observed attenuation of the characteristic gene expression profiles, including the IFN-pathway related genes (Fig. 3) . Interestingly, ICAM1 and MCP1 were part of a limited set of death ligand-induced genes that were not perturbed by the mutant version of FADD.
Coordinated Gene Expression Patterns Mediated by TRAIL and Interferons-The stimulation of IFN pathway genes by TRAIL led us to ascertain whether these genes would be induced by IFNs themselves in our in vitro cell system. Interferon-␣, -␤, or -␥ treatment of MCF7 cells indeed induced a widely concordant cluster similar to that obtained for 24 h treatment with death ligands (Fig. 4B) . This set of genes included classic IFN pathway genes such as STAT1, PKR, ISGF3␥, NMI, IFIT1, IFITM1, IFITM2, HLA molecules, PSME2, and PSMB10 (51). IFN-induced gene expression patterns were similar at both the 4-and 24-h time points. Treatment with IFN-␣, -␤, or -␥ plus TRAIL for 24 h led to up-regulation of two distinct clusters, apoptosis and NFB pathway-related genes (Fig. 4A) , and IFN pathway related genes (Fig. 4B) . In addition to the genes discussed earlier, we noted the up-regulation of other known IFN-induced genes not induced by TRAIL. These IFN pathwayspecific genes included guanylate cyclase activator protein (GUCA1A), GMP reductase, TNFR shedding aminopeptidase regulator (ARTS), RNA-specific adenosine deaminase (ADAR), butyrophyllin (BTN3A3), nucleoside-diphosphate kinase (NME5), IFN-induced guanylate-binding protein (GBP2), tryptophanyl t-RNA synthetase (WARS), bone morphogenetic protein (BMP3b/GDF10), and JAK-binding protein (also known as STAT-induced STAT inhibitor).
Characterization of Selected Genes Up-regulated by TRAIL and Interferons-We next corroborated our microarray results and examined some candidate genes involved in the molecular cross-talk between death receptor and IFN signaling. Up-regulation of TRAIL and caspase 7 by interferons and up-regulation of STAT1, MYD88, ISGF3␥, and IFN␥R2 by TRAIL are potential points of interaction between the two pathways identified by our microarray studies. We carried out Northern blot analyses of IFN-treated and TRAIL-treated samples using probes against caspase 7, TRAIL, MYD88, STAT1, ISGF3␥, and IFN␥R2, respectively (Fig. 5, A and B) . Probe hybridization intensities for each experimental condition were quantified by PhosphorImager. After normalization against GAPDH, a ratio was obtained between the experimental sample and its corresponding reference sample which provided a measure of fold up-regulation as assessed by Northern blot analysis. The fold up-regulation determined by Northern blot analyses and microarray analyses displayed remarkable qualitative concordance (Fig. 5C ). As has been previously observed by us (26, 27) , as well as others, we observed that Northern blot derived ratios were larger in magnitude compared with microarray ratios (Cy5/Cy3) for identical experiments. Thus spotted cDNA microarray analysis likely underestimates the fold difference between samples. For example, in cells treated with IFN␤ ϩ TRAIL for 24 h, caspase 7, TRAIL, MyD88, STAT1, and ISGF3␥ were shown to be 1.9-, 10.8-, 3.9-, 14.9-, and 4.2-fold up-regulated by microarray and 3.2-, 40.4-, 9.3-, 47-, and 10.8-fold up-regulated by Northern analysis, respectively (Fig. 5C ).
Caspase 7, TRAIL, and MyD88 were next assessed at the protein level by immunoblot analysis (Fig. 5D) . Highest levels of protein were detected in cells treated with IFN␤ and TRAIL. Since we observed up-regulation of STAT1, both by microarray and Northern blot analysis, we tested whether STAT1 undergoes phosphorylation in cells treated with TRAIL. Importantly, although IFN␤ or IFN␤ ϩ TRAIL-treated cells displayed phosphorylation of STAT1 (Tyr 701 ), STAT1 was not phosphorylated in cells treated with TRAIL or TRAIL ϩ CHX (Fig. 5E ). Consistent with this observation, it has been previously reported that STAT-1 is required for TNF-mediated cell death but its effect is not mediated through Tyr 701 phosphorylation of STAT1 (56) .
Mechanism of TRAIL-induced Activation of IFN-pathway
Related Genes-The unexpected cluster of IFN-pathway genes induced by TRAIL lead us to consider the possibility that if protein synthesis inhibition caused by CHX treatment is not absolute, then this cluster could in fact be representing a secondary response, mediated by TRAIL-induced primary response gene or genes. To address this possibility, we assessed the percent inhibition of protein synthesis in MCF7 cells at 4
FIG. 5. Corroboration of microarray data for genes regulated by TRAIL and interferons.
A, Northern blot analysis of interferon-treated samples assessed with probes against caspase 7, TRAIL, MyD88, STAT1, ISGF3␥, and GAPDH. GAPDH expression was used as a loading control. B, Northern blot analysis of TRAIL-treated samples assessed with probes against STAT1, ISGF3␥, MYD88, and IFN-␥R2. 28 S rRNA was used as the loading control. C, comparison between microarray data and Northern blot analyses for selected genes from A. Northern blot signal intensities were normalized against corresponding GAPDH signal intensities. The normalized values were used to calculate fold up-regulation for a given treatment using the ratio of test versus reference (for example, normalized ZC-TRAIL-24 h: normalized ZC-24 h ϭ fold up-regulation by TRAIL at the 24-h time point). Fold up-regulation as determined by Northern blot analysis was compared with fold up-regulation as obtained by microarray analysis (Cy5/Cy3 ratio of experimental with respect to reference sample). x Axes represent various treatments. y Axes on the left represent ratios obtained by Northern blot analyses and those on the right represent corresponding ratios obtained by microarray analysis. In most cases qualitative, but not necessarily quantitative, concordance between the two techniques was achieved. D, immunoblot analysis of TRAIL-and interferon-regulated proteins from MCF7 cells treated with combinations of zVAD, IFN-␤, or TRAIL for 24 h. Whole cell lysates were subjected to Western blot analysis using antibodies recognizing human caspase 7, TRAIL, and MyD88. Human ␤-tubulin was used as loading control. E, MCF7 cells were cultured in serum-free medium for 2 h and then treated with CHX, TRAIL, CHX ϩ TRAIL, IFN-␤, or IFN-␤ ϩ TRAIL for indicated times. Whole cell lysates were subjected to immunoblot analysis with an antibody specific for phosphorylated STAT-1 (Tyr 701 ). Levels of STAT-1 protein were detected by stripping and reprobing of the same blot with anti-STAT1 antibody.
and 24 h incubation with CHX, by metabolic labeling of cells with [
35 S]Met-Cys. CHX inhibited 90.1 and 78% protein synthesis at 4-and 24-h time points, respectively (Fig. 6A) . This suggested that a small, but significant, amount of protein synthesis remains in the CHX-treated cells. We next examined whether TRAIL-mediated induction of IFNs could result in activation of IFN pathway genes. Analysis of MCF7 cells treated with TRAIL for 24 h revealed induction of the Type I interferon, at the transcript and protein level, as detected by RT-PCR (Fig. 6B) and IP-Western of the treated cell lysates (Fig. 6C) , respectively. Presence of IFN␤ was detected in TRAIL-treated MCF7 cells irrespective of the presence of CHX (Fig. 6, B and C) . Lower levels of IFN␤ protein in TRAIL-and CHX-treated cells is presumably due to decreased protein synthesis. By contrast, the Type II interferon, IFN␥, did not exhibit altered transcript or protein expression as a result of TRAIL treatment (Fig. 6, B and D) . Taken together, these observations suggest that TRAIL induced synthesis of IFN␤ may account for the late cluster of genes induced by TRAIL.
TRAIL and Interferons Synergistically Induce Apoptosis of Breast Cancer Cells-Based on our microarray results, which suggest overlapping gene expression profiles between TRAIL and IFN, we hypothesized that these diverse cytokines may share a functional interaction. To test the effect of IFNs on apoptosis induced by TRAIL, we preincubated MCF7 and SUM149 cells with IFN-␣, -␤, or -␥ for 20 h and subsequently treated them with TRAIL. In both breast cancer cell lines, we observed an enhancement of apoptosis when TRAIL and IFNs were combined (Fig. 7, A and B) . The broad spectrum caspase inhibitor z-VADfmk completely blocked apoptosis induced by TRAIL and IFNs. Co-incubation, instead of preincubation, did not have a synergistic apoptotic effect in the time frame assessed (data not shown). IFN-␤ displayed highest synergistic effect among the three IFNs in both cell lines tested (Fig. 7B) and was thus examined further.
Enhanced Caspase Activation by TRAIL and Interferons-We next monitored cleavage of key death substrates and enzymes that indicate activation of the cell death machinery. Caspase 7 was an obvious target to examine, as we had identified its up-regulation by microarray (Fig. 4B) . Furthermore, caspase 8 was also examined since it is the apical caspase of death receptor signaling (1, 57) . Interestingly, levels of caspase 7 and 8 proteins were elevated by IFNs (Fig. 5D and 8A ). In addition, both caspases displayed enhanced proteolytic processing induced by combining TRAIL and IFNs (Fig. 8A) . The death substrates poly(ADP-ribose) polymerase and the BCL2 family member, Bid, displayed similar increased cleavage when TRAIL and IFN were combined (Fig. 8A) . Cleavage of Bid suggests synergistic activation of the mitochondrial arm of the apoptosis pathway (58, 59) .
Cleavage of caspase 8 being the nodal event leading to apoptosis, we measured caspase 8 activity in cells treated with TRAIL alone or in combination with interferon-␣, -␤, or -␥ (Fig.  8B ). Cells preincubated with IFNs and subsequently treated with TRAIL, displayed enhanced caspase 8 activity, further confirming the observed synergy. As expected, z-VAD effectively blocked TRAIL-and IFN-mediated caspase activity.
DISCUSSION
Relative to other TNF family members, TRAIL has received the most attention as a potential anti-cancer therapeutic (60 -63) . This is primarily the result of its ability to kill a broad range of neoplastic cells preferentially over normal cells without causing significant toxicity in animal models (4 -6) . The enthusiasm for TRAIL as a therapeutic subsided somewhat with the observation that recombinant TRAIL induces apoptosis of human hepatocytes in vitro (64) . Recent reports, contend, however, that the version of recombinant TRAIL used and how it is prepared can dictate the preferential anti-cancer killing activity of TRAIL (63, 65, 66) . Furthermore, addition of certain caspase inhibitors may also maintain preferential TRAIL activity (67) . The mechanism of this preferential activity likely involves a number of factors such as levels of death receptors, decoy receptors, and intracellular inhibitors including cFLIP and IAPs (6, 68) .
TRAIL binding to its cell surface receptors, DR-4 and DR-5, The intermediate cluster genes revealed more familiar players induced by the TNF family. A subset of these genes was identified by microarray analysis of cells treated with TNF and anti-Fas, and included cIAP2, IFN␥ receptor 2, NF-B p105, and MnSOD (88) . Many of these genes likely emerge from activation of NF-B and AP-1 transcription. Transcriptional regulators (NF-B, IB␣, JunD, BCL-6, and VDR) and chemokine family members (mCSF1, IFN␥R-2, MX-2, NK-4, MBL-2, MCP-1, -3, and -4) are also prevalent in this cluster. IFN pathway related genes such as IL-6 and IFN␥ receptor 2 begin to enter the "scene" at this stage.
Interferons are a family of related cytokines that play key roles in mediating antiviral, antigrowth, antitumor, and immunomodulatory responses (69, 70) . The primary signaling pathway involves tyrosine phosphorylation and activation of STATs, which subsequently orchestrate the expression of many genes that determine the multiple effects of IFNs. Ancillary pathways are also activated by the IFNs, but their effects on cell physiology are less clear. The Janus kinases, STATs, and numerous IFN-induced proteins, play important alternative roles in cells, raising questions as to how the responses to the IFNs intersect with more general aspects of cellular physiology and how the specificity of cytokine responses is maintained (51) . Microarray analysis of IFN-induced genes reported here shows overall concordance with an earlier report using oligonucleotide-based arrays (71) . They have noted the induction of PKR, IRF1, and STAT1 as representing pro-apoptotic effectors induced by IFNs, which were similarly picked up by our screen. Some novel IFN genes that we identified include caspase 7, MyD88, TLR3, NMI, among others.
A profound up-regulation of IFN-related genes is readily apparent in the late cluster of TRAIL-induced gene expression. Of note, we observed up-regulation of PKR, STAT1, ISGF3␥, HLA-C, and many others. A number of groups have reported links between the IFNs and the FADD-caspase 8 axis (72) (73) (74) (75) (76) . IFN and PKR, a double stranded RNA-dependent protein kinase induced by IFNs, have both been shown to signal apoptosis via FADD and caspase-8 (77) (78) (79) . Conversely, PKR and STAT1 have been shown to be required for TNF-mediated signaling (56, 80) . Functionally, IFNs and TNF alone are often not lethal, but in combination induce cell death (81) . TRAIL itself has been shown to be induced by IFNs (52-55, 82, 83) . To our knowledge this is the first study to demonstrate TRAILmediated induction of IFN␤. This suggests the presence of a hitherto unknown mutual cross-talk between the TRAIL and IFN signaling pathways. Further studies are needed to elucidate the molecular details of these interactions. IFN␤ transcription involves assembly of an enhanceosome protein complex comprised of NFB, IRF, ATP/c-Jun heterodimer together with HMGl(Y) protein binding cooperatively (84, 85) . Assembly of the enhanceosome leads to the recruitment of the transcriptional apparatus (86) leading to IFN␤ transcription. In the present work, TRAIL induced NF-B and AP1, which presumably mediated the induction of IFN␤, and consequent activation of IFN pathway genes. IFN␤ transcript is detectable by RT-PCR as early as 4 h and the protein was detected at the 24-h time point. The shared transcriptional programs likely contribute to the functional interaction between death signaling and IFN pathways.
Another important finding from our work is the significant overlap of gene expression patterns induced by TRAIL, TNF, and anti-Fas Ab, despite apparent differences between them. That said, TRAIL and TNF had "more similar" patterns than anti-Fas antibody, which may be due to differences between ligand and antibody-induced oligomerization of receptors. While classic NF-B dependent genes are induced by death ligands, we also observed activation of IFN-related genes. Regulation of gene expression by death ligands is mediated by FADD, since a dominant interfering mutant of this death adaptor molecule almost completely abolished differential gene expression. MCP1, B94, and ICAM were exceptions and not attenuated by FADD-DN.
TRAIL and IFNs synergistically induced caspase activation and apoptosis in breast cancer cells. Nodal points of interaction between the pathways that were characterized beyond microarray analysis include caspase 7, caspase 8, TRAIL, MyD88, STAT1, and ISGF3␥. While our study suggests pervasive interactions between these pathways, there are some important distinctions between TRAIL-and IFN-mediated gene expression. First, there are large clusters of genes that are specific to either IFNs or TRAIL alone. Second, TRAIL-induced IFN-related genes are revealed at a late time point (after 16 h), unlike IFNs, which generate detectable levels of these same transcripts within 4 h.
The molecular cross-talk and functional synergy observed between TRAIL and IFN signaling pathways may have therapeutic implications, especially if certain formulations of TRAIL are found to be nontoxic in humans (65, 87) . IFNs are well established biologic agents used as a treatment option for certain cancers (51) . By both activating the cell death pathway in tumor cells and modulating the immune response, combinations of IFN and TRAIL may have added anti-tumor activity. The present work suggests that combinations of IFN and TRAIL may have therapeutic efficacy in vivo. Defining gene expression signatures induced by anti-cancer agents (drugs or biologics) may suggest novel targets for therapeutic modulation.
